Comparison Study of Insulin GZR4 With Insulin Degludec
Launched by GAN AND LEE PHARMACEUTICALS, USA ·
Trial Information
Current as of September 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of insulin called Insulin GZR4 to see how it compares to two other insulins—Insulin Degludec (known as Tresiba®) and Insulin Icodec (Awiqli®)—which are already approved for treating type 2 diabetes in Europe. The goal is to understand if this new insulin works as well and is as safe as these existing options.
People with type 2 diabetes who are 18 years or older can take part in this study. Participants will be asked to use the insulin being tested or one of the approved insulins and will be closely monitored by the research team. This includes regular check-ins to track blood sugar levels and overall health. The study is currently open and looking for volunteers. If you or a family member has type 2 diabetes and is interested in new treatment options, this trial might be worth discussing with your doctor.
Gender
ALL
Eligibility criteria
About Gan And Lee Pharmaceuticals, Usa
Gan and Lee Pharmaceuticals, USA, is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for various medical conditions, particularly in the fields of diabetes and oncology. With a strong commitment to advancing healthcare, Gan and Lee Pharmaceuticals leverages cutting-edge technology and scientific expertise to deliver high-quality, affordable medications that improve patient outcomes. The company emphasizes rigorous clinical trials and regulatory compliance, ensuring that its products meet the highest standards of safety and efficacy. Through strategic partnerships and a focus on patient-centered solutions, Gan and Lee Pharmaceuticals is poised to make a significant impact in the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported